Former Chief Medical Officer · Immunovant, Inc. (IMVT)

Rita Jain

FY2020 is the first fiscal year CompBrief holds for Rita Jain as a named executive officer of Immunovant; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$13,512,984

Salary $101,137Stock awards $2,703,005Bonus $38,526

3rd of 5 named executive officers at Immunovant by FY2020 total.

5 named officers on file for Immunovant, FY2020

Rita Jain’s pay file — $29

  • 1 fiscal year of pay, line by line
  • IMVT’s disclosed peer group of 17 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Immunovant’s whole pay program stands against its peers

  • Immunovant’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on IMVT→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed August 12, 2021 (DEF 14A).

Free

Get Rita Jain’s full pay file as a PDF — free

More than this page: up to 10 years of Rita’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Rita Jain compensation by year

Immunovant Summary Compensation Table · the one fiscal year held
In US dollars, as Immunovant reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2020
Salary$101,137
Bonus$38,526
Stock awards$2,703,005
Option awards$10,666,997
Non-equity incentive$0
Pension and deferred compensation$0
All other$3,319
Total$13,512,984

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Immunovant, Inc. DEF 14A filed August 12, 2021, accession 0001764013-21-000083, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Immunovant, Inc. filed document, accession 0001764013-21-000083. Every figure is read from that document and cited to the page and table it appears in. Filed August 12, 2021.

Equity holdings

unvested awards at FY2021 year-end
TypeUnvested unitsValue at year-endExercise price
RSU97,600$1,565,504—
RSU20,000$320,800—
RSU11,765$188,711—
Option220,000—$42.19
Option342,300—$17.00

Per the Outstanding Equity Awards at Fiscal Year-End table in Immunovant, Inc.'s FY2021 proxy; value at the fiscal year-end close, as the company printed it.

Immunovant’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
Michael ElliottFormer Chief Scientific Officer$16,236,631
Peter SalzmannChief Executive Officer$15,375,304
Rita Jain · this pageFormer Chief Medical Officer$13,512,984
Julia ButchkoChief Development and Technology Officer$7,842,357
Pamela ConnealyChief Financial Officer (10)$5,602,705

The full Immunovant compensation record

free company brief

This page is one person within Immunovant's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Immunovant proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Immunovant's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Rita Jain's compensation dossier · One-time report. No refunds.